FINDINGS OF SCIENTIFIC MISCONDUCT
Release Date: September 10, 2002
NOTICE NUMBER: NOT-OD-02-069
Department of Health and Human Services
Notice is hereby given that the Office of Research Integrity (ORI) and
the Assistant Secretary for Health have taken final action in the
following case:
Zhenhai Yao, M.D., Ph.D., The University of North Carolina at Chapel
Hill: On August 20, 2002, the U.S. Public Health Service (PHS) entered
into a Voluntary Exclusion Agreement with The University of North
Carolina at Chapel Hill (UNC) and Zhenhai Yao, M.D., Ph.D., an
Associate Professor of Anesthesiology, School of Medicine at UNC.
Based on the UNC Report, the respondent"s admissions, and additional
analysis conducted by ORI in its oversight review, PHS found that Dr.
Yao engaged in scientific misconduct in research funded by the National
Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health
(NIH).
Specifically, PHS and UNC found that Dr. Yao:
(1) Falsified two flourescent micrographs for figures presented in
three NIH grant applications:
A. Figure 5, p. 28, in a funded grant application in 1 R01 HL067416-
01, "Mechanism of Preconditioning and Cardiac Apoptosis," submitted to
NIH on May 31, 2000,
B. Figure 6, p. 33, in a funded grant application in 1 R01 HL68250-01,
"Free Radicals, PKCd Signal Acetylcholine Preconditioning," submitted
to NIH on September9, 2000, and
C. Figure 7, p. 25, in an unfunded grant application in 1 R01 HL66230-
01A1, "Nitric Oxide and Opioid Preconditioning," Submitted to NIH on
July 2, 2001.
Dr. Yao falsely claimed that two fluorescent micrographs in the figure
represented neonatal rat cells transfected with an adenovirus-derived
vector, when the cells actually were chick cells transfected with a
cytomegalovirus-based vector, which he had taken from another scientist
at the University of Chicago.
(2) Falsified the same two fluorescence micrographs of CMV-transfected
chick cells described in Issue 1, above, by misrepresenting their
description as embryonic chick cells transfected with pcDNA, with and
without green fluorescent protein, for Figure 13 on p. 30 in an
unfunded NIH grant application, 1 R01 HL66230-01, "Molecular Mechanisms
of Opioids in Myocardial Ischemia," submitted January 21, 2000.
(3) Falsified a flow cytometry histogram in Figure 1B on p. 22 of NIH
application R01 HL66230-01A1, by claiming the histogram represented
results with rat myocardiocyte cultures treated with an opiate
antagonist (staurosporine).
However, this histogram had been published by Liu, H., McPherson, B.C.,
& Yao, Z. "Preconditioning Attentuates Apoptosis and Necrosis: Role
of Protein Kinase Ce and -d Isoforms." Am. J. Physiology Heart Circ
Physiol. 281:H404-H410, 2001, as Figure 1f showing the result from
embryonic chick cells treated for 12 hours with deoxy-glucose in the
absence of oxygen (simulated ischemia).
(4) Falsified claims about research results in NIH grant application
R01 HL66230-01A1, by claiming that data in Figure 3 on p. 23
represented experiments on cultures of neonatal rat cardiomyocytes as
an in vitro model of hypoxia-reoxygenation, shown as data from four
separate experiments measuring apoptosis by different means.
The data in the four separate experiments portrayed in Figure 3 are
identical to Figure 1, p. 2009, in the publication by Liu, H., Zhang,
H.Y., McPherson, B.C., Baman, T., Roth, S., Shao, Z., Zhu, X., & Yao,
Z. "Role of Opioid d1 Receptors, Mitochondrial KATP Channels, and
Protein Kinase C during Cardiocyte Apoptosis. J. Mol. Cell. Cardio.
33:2001-2014, 2001, which were reported as the results from experiments
on cultures of embryonic chick cardiocytes.
(5) Falsified the micrographs in panels a and d, Figure 1, p. 2009, in
the publication by Liu, H. et al., J. Mol. Cell. Cardiol. 33:2001-2014,
2001, by claiming they represented TUNEL data showing normal media and
opioid antagonist (BTNX)-treated cultures of chick cardiocytes,
respectively.
The same micrographs had been reported by Liu, H. et al., Am. J.
Physiology Heart Circ Physiol. 281:H404-H410, 2001, in Figure 1 (panels
a and e) and in Figure 2 (panels a and b), as representing cardiocyte
cultures exposed for 24 hours to deoxy-glucose and no oxygen (simulated
ischemia).
(6) Falsified the physiological effects of gene transduction into
hearts, by copying and re-using the same pressure tracing for untreated
rates as he did for rats purportedly treated by intracardial injection
with adenovirus (AdEGFP) in:
A. Figure 11, p. 26, in unfunded NIH grant application R01 HL66230-
01Al,
B. Figure 9, p. 30, in funded NIH grant application R01 HL67416-01,
C. Figure 9, p. 34, in funded NIH grant application R01 HL68250-01,
and
D. Figure 8, p. 30, in funded NIH grant application 1 K08 HL03881-01.
(7) Falsified data in panels c and d in Figure 13, p. 26, in NIH grant
application R01 HL66230-01A1. Dr. Yao claimed that panel c represented
a TUNEL assay on histological sections of myocardium from a rat
transfected with Ad. gal and subjected to ischemia-reperfusion and that
panel d represented a tissue section from a rat transfected with
Ad.PKCd-FL.
Panel c is a horizontally compressed copy of panel b, purported to be a
non-transfected rat subjected to ischemia-reperfusion, and panel d is a
horizontally expanded version of panel a, purported to be a sham-
operated, non-transfected control.
(8) Falsified the claims about the micrograph of ischemic data ("panel
b" in issue 7, above) reported as:
A. Figure 11, p. 31, in R01 HL67416-01 (submitted May 31, 2000), and
B. Figure 12, p. 35, in R01 HL68250-01 (submitted September 29, 2000).
In both examples, the figures, which are identical, consist of two
panels purported to be TUNEL data showing sham operated controls (panel
a) and the effect of transient ischemia for 30 minutes (panel b).
However, these data are identical to Figure 10, p. 32, in NIH
application K08 HL03881-01, reported a control and the effect of
nontransient ischemia, i.e., 20 hours of ischemia followed by 24 hours
of reperfusion.
(9)Falsified data in Figure 14 on p. 27 in NIH grant application R01
HL66230-01A1, as representing a gel electophoresis data from an in vivo
experiment on rat myocardial ischemia.
However, the same data was represented as Figure 3, p. 23, of the
application (and also as in Figure 1, J. Cell. Mol. Cardiol. 33:2007-
2014, 2001), as results from a study of embryonic chick heart cell
cultures for the effect of preconditioning on opioid receptors.
Furthermore, Dr. Yao falsified the stated size of the fragments in the
DNA marker ladder by altering the position of the molecular weight
markers in Figure 14.
(10) Falsified Figure 3, p. 27, in 1 R01 HL67416-01, a DNA-laddering
gel electrophoresis experiment, showing that apoptosis in cardiocyte
cultures is significantly increased by staurosporin and by 12 hours of
simulated ischemia.
The same data was shown in Figure 1, p. 26, in application HL03881-07
showing that apoptosis is significantly increased by 10 ?M NE and by 15
nM TNF-a.
The research misconduct was significant because Dr. Yao"s research
involved the fundamental mechanisms for cardiac cell injury and
pathogenesis after a heart attack. The falsified data were significant
to reviewers" opinions on funding because they were advanced as
preliminary results showing successful new experiments extending his
experimental model to adult rat hearts.
Dr. Yao has entered into a Voluntary Exclusion Agreement in which he
has voluntarily agreed:
(1) to exclude himself from any contracting or subcontracting with any
agency of the United States Government and from eligibility for, or
involvement in, nonprocurement transactions (e.g., grants and
cooperative agreements) of the United States Government as defined in
45 C.F.R. Part 76 (Debarment Regulations) for a period of five (5)
years, beginning on August 20, 2002,
(2) to exclude himself from serving in any advisory capacity to PHS,
including but not limited to service on any PHS advisory committee,
board, and/or peer review committee, or as a consultant for a period of
five (5) years, beginning on August 20, 2002, and
(3) to submit a letter to the Journal of Molecular and Cellular
Cardiology requesting retraction of Figure 1 in the article by Hui Liu,
et al., J. Mol. Cell. Cardiol. 33:2001-2014, 2001, within 30 days of
notification of this action. This requirement will be noted on the
ALERT System until Dr. Yao sends a copy of the retraction letter to
ORI.
INQUIRIES
For further information contact:
Director
Division of Investigative Oversight
Office of Research Integrity
5515 Security Lane, Suite 700
Rockville, MD 20852
Telephone: 301-443-5330
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
|
|
|
|
Department of Health and Human Services (HHS)
|
|
|
|
NIH... Turning Discovery Into Health®
|